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Three murine monoclonal antibodies (MAb), E19, E205, and E251, raised against pertussis toxin reacted in
Western blots (immunoblots) with the Si, S4, and S2-S3 subunits, respectively, and neutralized the Chinese
hamster ovary cell-clustering activity of pertussis toxin. MAb E251 recognized a linear synthetic peptide
corresponding to amino acids 107 to 120 of the S2 subunit, suggesting a role for this region in receptor binding.
Pertussis toxin (PT) is secreted from virulent Bordetella
pertussis and is responsible for a number of biological
effects, including histamine sensitization, islet activation,
and lymphocyte promotion, which may contribute signifi-
cantly to the severity of whooping cough (18, 19, 23).
Pertussis holotoxin contains subunits Si, S2, S3, S4, and S5
in a ratio of 1:1:1:2:1 and consists of an A protomer (Si
subunit), which contains the enzymatic ADP ribosyltrans-
ferase and NAD glycohydrolase activities of the toxin, and a
B oligomer (S2 to S5 subunits),which is involved in receptor
binding (9). The PT receptor-binding pockets are contained
within the S2 and S3 subunits (24, 25). Although PT is one of
the major protective antigens against whooping cough (18,
19), concern regarding the observed side effects of immuni-
zation has resulted in strategies for the chemical and genetic
detoxification of PT (2, 12, 15, 17). To identify regions of the
toxin molecule that contribute to the biological activity of
PT, we have raised monoclonal antibodies (MAb) that rec-
ognize linear epitopes of the Si, S2-S3, and S4 subunits of
PT as determined by Western blot (immunoblot) analysis
and that neutralize the toxic effect ofPT on Chinese hamster
ovary (CHO) cells.
BALB/c mice were immunized with glutaraldehyde-detox-
ified PT (16) and MAb raised essentially as previously
described (30). The myeloma used in the fusion experiment
was X63Ag8 (10). Hybridoma supernatant fluids were
screened for PT subunit recognition by Western blot analysis
carried out essentially as described by Burnette (3) and by
inhibition of CHO cell clustering (7, 8) as described by Sato
et al. (22). PT was electrophoresed through a polyacrylamide
gel by the method of Laemmli (13) by using a 3.85%
acrylamide stacking gel and a 15% acrylamide separating gel.
MAb E19 bound to the Si subunit (Fig. 1A, lane 2), MAb
E251 reacted strongly with the S2 subunit and weakly with
the S3 subunit (Fig. 1A, lane 3), and MAb E205 reacted with
the S4/S5 doublet (Fig. 1A, lane 4). To determine which of
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the subunits was recognized by MAb E205, the reaction was
repeated with purified S4 and S5; this revealed that E205
recognizes the S4 subunit of PT (Fig. 1B). E19, E205, and
E251 were subclassed by use of an MAb subclassing kit
(Dianova) as immunoglobulin Gl heavy-chain and kappa
light-chain antibodies (results not shown). The three anti-PT
antibodies were purified from hybridoma supernatant fluids
by using a Pharmacia protein A-Sepharose CL-4B column
(4). The antibody preparations consisted of a 26-kDa light-
chain band and a 55-kDa heavy-chain band after electropho-
resis (data not shown). All three MAb neutralized PT clus-
tering of CHO cells, whereas antibody 13C4 (28), directed
against the B subunit of Shiga-like toxin, did not (Table 1).
The ability of MAb E19 to inhibit the ADP ribosylation of
bovine transducin was compared with that of rabbit poly-
clonal anti-Si antiserum. The MAb (1.1 mg/ml) or antiserum
was serially diluted in phosphate-buffered saline, and 20 ,ul
of each antibody dilution was incubated with 1 ,ul of PT (0.1
,ug/ml) for 30 min at room temperature. After toxin activa-
tion by the addition of 5 pul of 250 mM dithiothreitol for 1 h
at room temperature, 4 IlI of bovine eye transducin (G
protein substrate for PT-mediated ADP ribosylation;
1-mg/ml concentration), 2.5 pAl of 1 M Tris-Cl (pH 8.0), 10 ,lI
of 10 mM ATP, 7 RI of H20, and 0.1 RI of [adenylate-
32P]NAD (50 mCi/ml; NEN) were added and the mixture
was incubated at room temperature for 2 h. The mixtures
were passed through cellulose nitrate filters (Schleicher &
Schuell) which were subsequently washed with 50 mM
Tris-CI-5 mM MgCl2 (pH 8.0). ADP-ribosylated transducin
was detected after scintillation counting of filters. Clearly,
the preincubation of PT with MAb E19 inhibits the ADP
ribosylation activity of the toxin (Fig. 2).
The epitope recognized by MAb E251 was identified by
screening for binding to a bank of synthetic peptides corre-
sponding to regions of the S2 subunit protein sequence
predicted to contain surface-exposed hydrophilic ,B turns
(25, 26). E251 reacted strongly with a peptide corresponding
to amino acids 107 to 120 (TATRLLSSTNSRLC; amino acid
one-letter code) of the mature protein in enzyme-linked
immunosorbent assays (ELISAs) when either the free pep-
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FIG. 1. Western blot analysis of PT binding by MAb. (A) PT was
subjected to electrophoresis and blotted with polyclonal mouse
antiserum (lane 1) and MAb E19 (lane 2), E251 (lane 3), and E205
(lane 4). Coomassie blue-stained toxin is shown in lane 5. PT
subunits are indicated by arrows. (B) Purified subunits S4 and S5
were subjected to electrophoresis and blotted with MAb E205. Lane
1 contains Coomassie blue-stained Bio-Rad molecular weight mark-
ers (sizes indicated by arrows), lanes 2 and 4 contain the S5 subunit,
and lanes 3 and 5 contain the S4 subunit. Lanes 2 and 3 are stained with
Coomassie blue, whereas lanes 4 and 5 are Western blots with E205.
tide or its bovine serum albumin (BSA) conjugate was used
to coat the ELISA plate (Fig. 3). Previous work employing
antibodies raised against peptides as sequence-specific
probes for the localization of the receptor-binding pocket of
PT suggested involvement of amino acid residues 1 to 7, 35
to 59, and 91 to 106 of the S2 subunit (25, 26) and corre-
sponding regions in the S3 subunit (24).
Numerous PT-specific MAb have been obtained (1, 5, 6,
11, 14, 20-22, 27), but few have been characterized with
respect to their ability to interfere with PT binding activity
(5, 14). Frank and Parker (6) described an S2-reactive MAb
which did not neutralize PT in an in vivo histamine-sensitiz-
TABLE 1. Neutralization of the PT-mediated clustering of CHO
cells by MAb E19, E205, and E251
CHO cell-clustering activity of PTa preincubated
Final MAb with the following MAb for 5 min at room tempb:
concn (jig/ml)
E19 E205 E251 13C4
10.0 ++ ++ ++
1.0 ++ ++ ++
0.1 - ++ +
0.01 - + -
a Final concentration, 6 ng/ml.
b PT-MAb mixtures were added to 1 ml of CHO cells diluted to 105 cells/ml
in 24-well tissue culture plates. Inhibition of PT-mediated CHO cell clustering
was scored after growth at 37°C for 2 days. Symbols: ++, inhibition of
clustering activity; +, partial inhibition of clustering activity; -, no inhibition
of CHO cell-clustering activity.
antiserum dilution
FIG. 2. Inhibition of ADP ribosylation (ADPR) activity of PT by
purified MAb E19 (filled squares) or anti-Si rabbit polyclonal
antiserum (open squares). The level of PT ribosylation of bovine eye
transducin (G protein substrate for PT-mediated ADP ribosylation)
without the addition of antibodies is indicated by a dashed line.
Standard deviations of triplicate samples are indicated by vertical bars.
ing assay. Sato et al. (20) described another S2-specific MAb
which was inhibitory in the CHO cell-clustering assay, and
S3-reactive MAb which neutralized PT in the CHO cell-
clustering assay and/or in a histamine-sensitizing assay have
been reported by Anwar et al. (1) and Schou et al. (27). Lang
et al. (14) have described MAb that recognize conforma-
tional epitopes of S2-S4 and S3-S4 dimers which inhibited
PT-mediated CHO cell clustering and binding of PT to CHO
cells. However, none of the epitopes recognized by neutral-
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FIG. 3. Determination of the epitope recognized by MAb E251.
An ELISA of BSA-conjugated peptides (hatched bars) and free
peptides (filled bars) with E251 as the primary antibody (undiluted
hybridoma supernatant) is shown. The peptides correspond to
regions of the S2 subunit protein sequence and have been described
elsewhere (25, 26). Undiluted hybridoma supernatant from E55,
which bound the S2 and S3 subunits of PT in Western blots but did
not neutralize CHO cell-clustering activity, did not bind any of the
peptides tested (results not shown).
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NOTES 4251
izing MAb reported thus far has been mapped. Here we
report localization of the binding site of the inhibitory MAb
E251 to amino acids 107 to 120 of the S2 subunit, which is
adjacent to the segment of S2 previously implicated in
receptor recognition (25). Interestingly, in an ELISA, E251
recognizes the corresponding segment of the S3 subunit
containing amino acids 104 to 117 only very weakly as a free
peptide and not at all when the peptide is conjugated to BSA
(results not shown). The core region of the two peptides
differs only by a conservative alanine (S3) to serine (S2)
exchange at position 113.
The identification of regions that are involved in the
biological activity of PT not only provides insights into the
structure-function relationship of the toxin molecule but also
specifies epitopes in which an immune response may play an
important role in protection. This, combined with recent
advances in the "humanization" of murine MAb (29), should
lead to the production of anti-PT antibodies applicable to
humans that may prove effective in providing passive pro-
tection (21) against pertussis in the nonimmunized newborn.
PT isolated from B. pertussis was a kind gift from S. Cryz,
whereas isolated S4 and S5 subunits were from C. Capiau and
purified bovine eye transducin was provided by P. Gierschik. We
thank B. Jansen, G. Kreissel, and U. Seitz for expert technical
assistance. MAb cell line ATCC CRL 1794, which produces MAb
13C4, was obtained from the American Type Culture Collection.
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